A5084339876- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Brain Metastases and Treatment
- Medical Imaging Techniques and Applications
- RNA modifications and cancer
- Immune Cell Function and Interaction
- Management of metastatic bone disease
- Heavy Metal Exposure and Toxicity
- Ferroptosis and cancer prognosis
- Histone Deacetylase Inhibitors Research
- Radiopharmaceutical Chemistry and Applications
- Selenium in Biological Systems
- Boron Compounds in Chemistry
- Peptidase Inhibition and Analysis
- Epigenetics and DNA Methylation
- Free Radicals and Antioxidants
- Trace Elements in Health
- Cancer Cells and Metastasis
- Metal complexes synthesis and properties
- Redox biology and oxidative stress
University of Gothenburg
2021-2025
Sahlgrenska University Hospital
2021-2025
Region Västra Götaland
2024
Center for Cancer Research
2023
Wallenberg Wood Science Center
2023
Selenium homeostasis depends on hepatic biosynthesis of selenoprotein P (SELENOP) and SELENOP-mediated transport from the liver to e.g. brain. In addition, maintains copper homeostasis. metabolism are inversely regulated, as increasing decreasing selenium levels observed in blood during aging inflammation. Here we show that treatment increased intracellular SELENOP hepatocytes decreased extracellular levels. Hepatic accumulation is a characteristic Wilson's disease. Accordingly, were low...
Background: Metastatic organotropism in lung cancer significantly influences prognosis, yet current treatment and clinical management guidelines are largely generalized for metastatic disease, regardless of organ site involvement. Notably, up to 30% non-small cell (NSCLC) patients present with brain metastases (BM) at diagnosis, underscoring the need a more nuanced understanding patterns. However, real-world data on well-characterized patient cohorts remain surprisingly scarce. Here, we...
Abstract Background In non-small cell lung cancer (NSCLC), the rapid advancement of predictive genetic testing tumors by identifying specific pathogenic driver variants has significantly improved treatment guidance. However, immune checkpoint blockade (ICB) is typically administered to patients with in absence such variants. Since only about 30% will respond ICB treatment, novel biomarkers clinical response crucial and improve decisions. This prospective study aims combine molecular biology,...
Background: Brain metastases (BM) are a major clinical challenge in metastatic lung adenocarcinoma (LUAD), affecting up to 50% of patients during disease progression. Current guidelines do not mandate brain imaging for all cancer at diagnosis unless there neurological symptoms present. However, real-world data on the predictive value BM detection remain scarce. Methods: This retrospective multicenter study analyzed consecutive diagnosed with stage IV LUAD molecular assessment western Sweden...
Background Metastatic organotropism in lung cancer significantly influences prognosis, yet current treatment and clinical management guidelines are largely generalized for metastatic disease, regardless of organ site involvement. Notably, up to 30% non-small cell (NSCLC) patients present with brain metastases (BM) at diagnosis, underscoring the need a more nuanced understanding patterns. However, real-world data on well-characterized patient cohorts remain surprisingly scarce. Here, we...
Introduction: Immune checkpoint blockade (ICB) is a standard first-line treatment for advanced-stage non-small cell lung cancer (NSCLC) without actionable oncogenic alterations. KRAS mutations, prevalent in 30-40% of Western adenocarcinomas, currently lack targeted therapies. This study aimed to assess the predictive value mutations clinical outcomes following ICB, validating previous findings larger cohort with extended follow-up. Methods: We conducted retrospective multicenter including...
There is an urgent need to identify new predictive biomarkers for treatment response both platinum doublet chemotherapy (PT) and immune checkpoint blockade (ICB). Here, we evaluated whether outcome could be affected by KRAS mutational status in patients with metastatic (Stage IV) non-small cell lung cancer (NSCLC). All consecutive molecularly assessed diagnosed between 2016−2018 Stage IV NSCLC the region of West Sweden were included this multi-center retrospective study. The primary study...
Immunotherapy by blocking programmed death protein-1 (PD-1) or protein-ligand1 (PD-L1) with antibodies (PD-1 blockade) has revolutionized treatment options for patients non-small cell lung cancer (NSCLC). However, the benefit of immunotherapy is limited to a subset patients. This study aimed investigate value combining immune and genetic variables analyzed within 3-4 weeks after start PD-1 blockade therapy predict long-term clinical response.Blood collected from NSCLC were changes in...
Pulmonary adenocarcinoma (ADC) is a very diverse disease, both genetically and histologically, which displays extensive intratumor heterogeneity with numerous acquired mutations. ADC the most common type of lung cancer believed to arise from in situ (AIS) then progresses minimally invasive (MIA). In patients European ethnicity, we analyzed genetic mutations AIS (
Abstract Introduction Stage III non-small cell lung cancer (NSCLC) is heterogeneous and identification of subgroups with differential responses crucial to optimize treatment. Addition durvalumab concurrent chemoradiotherapy (cCRT) has previously been shown improve survival outcomes. Meanwhile, harboring KRAS mutations have worse prognosis. We investigated whether mutational status may affect outcomes after adjuvant following cCRT in stage NSCLC. Methods In this retrospective study, we...
mutation status is a well-established independent prognostic factor in advanced non-small cell lung cancer (NSCLC), yet its role early-stage disease unclear. Here, we investigate the value of combining survival data on
Abstract Lung cancer is primarily a disease of the elderly. Despite shared molecular changes between aging and 1 – such as permissive chromatin states deregulated protein homeostasis studies on physiologically aged models human lung are lacking. Here, we show that alters progression KRAS-driven non-small cell (NSCLC), promoting metastasis while suppressing primary tumor growth. Clinically, multicenter analysis all consecutively diagnosed NSCLC cases in Western Sweden over 3-year period...
Abstract Purpose There is an urgent need to identify new predictive biomarkers for treatment response both platinum doublet chemotherapy (PD) and immune checkpoint blockade (ICB) with pembrolizumab. Here we evaluated whether outcome could be affected by KRAS mutational status in patients metastatic (stage IV) non-small cell lung cancer (NSCLC). Methods All consecutive molecularly assessed diagnosed between 2016-2018 stage IV NSCLC the region of West Sweden were included this multi-center...
Abstract Background KRAS mutation status, stage and tumor size at the time of diagnosis are well-established independent prognostic factors in non-small cell lung cancer (NSCLC). Here, we investigate value combining survival data on status early-stage NSCLC. Methods We studied combined impact mutational overall (OS) risk death patients with I-II performed a retrospective study including 310 consecutively diagnosed early (stage I-II) NSCLCs. All consecutive molecularly assessed between...
Abstract Blockade of PD-1/PDL1 (PD-1 blockade) with antibodies has revolutionized treatment options for non-small cell lung cancer (NSCLC) patients tumors without targetable mutations. The benefit PD-1 blockade is limited only to a subset the patients. This study aims identify biological markers clinical response in discovery cohort (n=15) early during distinguish responders from nonresponders using immunological and genetic markers. Immune subsets identified blood are characterized...
<h3>Background</h3> Blockade of PD-1 or PD-L1 (PD-1 blockade) with antibodies has revolutionized treatment options for patients non-small cell lung cancer particularly tumors that don't present any targetable mutations. However, the benefit blockade is limited only to a subset patients. This study aims identify biological markers clinical response in discovery and validation cohort early on during distinguish responders from non-responders. <h3>Methods</h3> Blood was drawn cancer, at...